BriSTAR Immunotech

Company Drug

BriSTAR Immunotech’s LILRB4-Targeted Cell Therapy YTS104 Gets Tacit Approval for Clinical Trial in China

Fineline Cube Jan 24, 2024

BriSTAR Immunotech, a clinical-stage cell therapy company based in Beijing, has received tacit clinical trial...

Company Deals

AstraZeneca Secures Full Global Rights to AbelZeta’s C‑CAR031 in $630M CAR‑T Deal

Company Drug

Novartis’s Ianalumab Wins FDA Breakthrough Therapy Designation for Sjögren’s Disease

Company Deals

Medtronic and Precision Neuroscience Form First Brain‑Device Alliance to Access Neural Data

Company Drug

Akeso’s Gumokimab NMPA Filing for Ankylosing Spondylitis Expands IL‑17A Franchise